153 related articles for article (PubMed ID: 9529672)
1. Usefulness of 18FDG positron emission tomography in detection and follow-up of digestive cancers.
Paulus P; Hustinx R; Daenen F; Jacquet N; Rigo P
Acta Gastroenterol Belg; 1997; 60(4):278-80. PubMed ID: 9529672
[TBL] [Abstract][Full Text] [Related]
2. [Value of [18F]-fluorodeoxyglucose (FDG) positron emission tomography in digestive cancerology].
Montravers F; Kerrou K; Grahek D; Zerbib E; Mabille L; Younsi N; Petegnief Y; De Beco V; Colombet-Lamau C; Talbot JN
Presse Med; 2002 Oct; 31(33):1560-8. PubMed ID: 12422485
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
4. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of FDG PET in evaluation of cancer patients.
Kostakoglu L; Agress H; Goldsmith SJ
Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
[TBL] [Abstract][Full Text] [Related]
6. [PET and digestive cancers].
Talbot JN; Montravers F; Gutman F; Kerrou K; Huchet V; Grahek D; Andre T; Houry S; Touboul E; Rosmorduc O; Poupon R; Ruszniewski P; Rougier P; Grange JD
Presse Med; 2008 Feb; 37(2 Pt 2):e1-e24. PubMed ID: 17951024
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography in colorectal cancer.
Flamen P
Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
[TBL] [Abstract][Full Text] [Related]
8. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
9. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
[TBL] [Abstract][Full Text] [Related]
10. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
11. The clinical application of positron emission tomography to colorectal cancer management.
Arulampalam TH; Costa DC; Bomanji JB; Ell PJ
Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814
[TBL] [Abstract][Full Text] [Related]
12. Role of FDG-PET scan in staging of cancer of the esophagus and gastroesophageal junction.
Lerut T; Flamen P
Minerva Chir; 2002 Dec; 57(6):837-45. PubMed ID: 12592225
[TBL] [Abstract][Full Text] [Related]
13. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
14. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
15. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.
Gauthé M; Richard-Molard M; Cacheux W; Michel P; Jouve JL; Mitry E; Alberini JL; Lièvre A;
Dig Liver Dis; 2015 Jun; 47(6):443-54. PubMed ID: 25766918
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
Reske SN; Kotzerke J
Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography imaging in evaluation of cancer patients.
Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.
Vitola JV; Delbeke D; Sandler MP; Campbell MG; Powers TA; Wright JK; Chapman WC; Pinson CW
Am J Surg; 1996 Jan; 171(1):21-6. PubMed ID: 8554144
[TBL] [Abstract][Full Text] [Related]
19. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
Flamen P; Lerut A; Van Cutsem E; Cambier JP; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L
J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review.
Akin EA; Qazi ZN; Osman M; Zeman RK
Abdom Radiol (NY); 2020 Apr; 45(4):1018-1035. PubMed ID: 32152644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
